If you think the broader market’s extreme pendulum swings are the definition of volatility, you should have a conversation with long-term investors of vaccine specialist Novavax (NVAX). To quickly recap the last 24 months: In 2018, the stock gained 73%, paid it back with interest during a 90% slide in 2019, and is back to gaining again. Unlike most other names, so far in 2020, the small cap biotech is up by a jaw dropping 198%. Yesterday, Novavax added another 20% to its share price. So, the recent surge must be COVID-19 related, right? Well, yes and no. Novavax has …read more
Source:: Yahoo Finance
